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Abstract
Introduction: Osteoporosis is a major public health problem leading to morbidity and mortality in many individuals. Treatment for
osteoporosis has generally relied on mechanisms that decrease osteoclastic bone resorption. This review outlines new evidence that the
cholesterol synthetic pathway may be important in bone metabolism and that 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA)
reductase inhibitors or statins may increase bone formation. Results: An experimental observation reported that statins increase bone
formation in rodents and that statins have an important role for the cholesterol synthetic pathway in bone formation. This may be via potent
bone-forming growth factors, the bone morphogenetic proteins (BMPs). Subsequent epidemiological studies (including a meta-analysis of
8 studies) have suggested that statin use may be associated with increased bone mineral density (BMD) and decreased fracture risk in
humans. However, more recently published studies have challenged the effect on fracture risk. Conclusion: The effect of statins on bone
mineral density and fracture risk in retrospective studies suggests an exciting new direction for research in bone formation that may lead
to advances in the therapy of osteoporosis.
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